Parvovirus <scp>B19</scp>‐associated graft failure after allogeneic hematopoietic stem cell transplantation

Rattani, Nabila; Matheny, Christina; Eckrich, Michael J.; Madden, Lisa; Quigg, Troy C.

doi:10.1002/cnr2.1403

Cited by 11 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…B19V's hematological involvement has also been described in cases of graft failure in the pediatrics cases report. 20 We summarized prior cases reports of B19V infections in alloHSCT patients in Appendix 2. B19V PCR in bone marrow seems more sensitive than in blood: in our study nine patients with cytopenia had B19V PCR performed both in blood and bone marrow:…”

Section: Discussionmentioning

confidence: 99%

Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study

Sammut,

Feghoul,

Xhaard

et al. 2023

Transplant Infectious Dis

View full text Add to dashboard Cite

BackgroundHuman parvovirus B19 (B19V) infection is associated with pure red cell aplasia (PRCA) in immunocompromised patients; however, the spectrum of manifestations associated with B19V in allogeneic hematopoietic stem cell transplantation recipients (alloHSCT) has rarely been reported.MethodsIn this study, we aimed to report clinical and immune features of B19V infection after alloHSCT. We retrospectively collected and analyzed clinical and microbiological data of all transplanted patients with B19V DNAmia or tissue infection detected by polymerase chain reaction (PCR) in our center from 2010 to 2021.ResultsWe report 35 cases of B19V infections in 33 patients. Median time from transplant to B19V first PCR positivity was 6.9 months (interquartile range (IQR) [1.6–18.9]). No preferential immune profile, type of transplantation or conditioning was identified. Hematological impairment was the most frequent sign, followed by rash and fever. Unconventional clinical forms were also detected, such as acute myelitis and myositis. For some cases, the direct relationship between symptoms and B19V infection was difficult to prove but was suggested by targeted tissue PCR positivity. When hematological impairment was not at the forefront, reticulocytopenia helped to diagnose B19V infections. Treatment was mainly based on high dose intravenous immunoglobulin.ConclusionAlthough hematological impairment was the most frequent sign, B19V can affect multiple targets and lead to atypical manifestations. Because of its heterogeneous clinical presentation, B19V infection is likely under‐diagnosed. Diagnosis of unusual B19V organ involvement needs combination of arguments which can include targeted tissue PCR. image

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study

Sammut,

Feghoul,

Xhaard

et al. 2023

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Erythema infectiosum or arthropathy occurs in healthy children or adults ( 29 ). In immunocompromised patients, bone marrow transplant recipients ( 10 ) or patients with hemopathy, the infection can lead to autoimmune hemolytic anemia, neutropenia, thrombocytopenia, acute pure red cell aplasia (PRCA), transient aplastic crisis (AC), and rarely HLH ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

“…It is associated with pure red cell aplasia (PRCA) ( 2 – 4 ), viral myocarditis ( 5 – 8 ), erythema infectiosum ( 9 ), and other clinical manifestations. At the same time, evidence of the presence of parvovirus B19 has also been found in bone marrow transplant recipients ( 10 ) and diseases such as systemic lupus erythematosus ( 11 , 12 ), miscarriage ( 13 ), systemic sclerosis ( 14 ), hereditary hemolytic anemias ( 15 ). Infectious erythema is one of the most common clinical manifestations of parvovirus B19 infection, which often occurs in children ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Case Report: Parvovirus B19 infection complicated by hemophagocytic lymphohistiocytosis in a heart-lung transplant patient

et al. 2023

View full text Add to dashboard Cite

Immunosuppressed patients can contract parvovirus B19, and some may experience hemophagocytic lymphohistiocytosis (HLH). Herein, we describe the first report of hemophagocytic lymphohistiocytosis in a heart-lung transplant patient with concomitant parvovirus B19 infection. The patient was treated with intravenous immune globulin (IVIG) and the features of HLH were remission. This instance emphasizes the significance of parvovirus B19 monitoring in transplant patients with anemia; if HLH complicates the situation, IVIG may be an adequate remedy. Finally, a summary of the development in diagnosing and managing parvovirus B19 infection complicated by HLH is provided.

show abstract

“…Rattani et al, 2022 51 Two case reports B19V infection might be a risk factor for secondary graft failure after HCT. Both patients described had decreasing donor cell chimerism post-transplantation in combination with anemia or pancytopenia.…”

Section: Waruiru Et Al 2007 28mentioning

confidence: 99%

Parvovirus B19 infection in pediatric allogeneic hematopoietic cell transplantation – Single‐center experience and review

Holterhus

Hennies

Hillmann

et al. 2023

Transplant Infectious Dis

View full text Add to dashboard Cite

Background Parvovirus B19 (B19V) infection following pediatric hematopoietic cell transplantation (HCT) is a rare complication and available data is scarce. Therefore, we present the experience with B19V Infection in allogeneic pediatric HCT recipients at our transplant center together with a systematic review of the literature. Methods Pediatric HCT patients with Parvovirus B19 infection treated at the University Children's Hospital Münster between 1999 and 2021 were retrospectively identified and clinical data were analyzed. Additionally, a systematic MEDLINE search to identify relevant articles was performed. Results We identified three out of 445 patients (0.6%) with B19V infection post‐transplantation. B19V infection occurred in combination with other complications like Graft‐versus‐Host disease, additional infections, or autoimmune‐mediated hemolysis potentially triggered by B19V. In one patient these complications lead to a fatal outcome. The review of the literature showed considerable morbidity of B19V infection with the potential for life‐threatening complications. Most patients were treated by red blood cell transfusion and intravenous immunoglobulins (IVIG) with a high succession rate. Conclusion Symptomatic B19V infection following HCT remains a rare but potentially challenging complication. A causal antiviral therapy does not exist as well as general recommendations on dosage and duration of IVIG therapy. Despite this, most patients are treated successfully with these measures. Additionally, transmission via blood or stem cell products is also rare and no general recommendations on B19V screenings exist.

show abstract

Parvovirus B19‐associated graft failure after allogeneic hematopoietic stem cell transplantation

Cited by 11 publications

References 17 publications

Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study

Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study

Case Report: Parvovirus B19 infection complicated by hemophagocytic lymphohistiocytosis in a heart-lung transplant patient

Parvovirus B19 infection in pediatric allogeneic hematopoietic cell transplantation – Single‐center experience and review

Contact Info

Product

Resources

About